Isolagen pivotal study
This article was originally published in The Gray Sheet
Executive Summary
Initial stage of 158-patient Phase III trial for autologous cellular skin therapy is completed. The technology, which the firm plans to launch in 2005, cultures a skin biopsy from behind the ear and implants newly grown fibroblasts in order to regenerate collagen (1"The Gray Sheet" Feb. 16, 2004, p. 16). Early study results show 77% efficacy at four months. Isolagen expects efficacy to improve over six months of follow-up...
You may also be interested in...
Aesthetic Technologies Forum In Brief
Isolagen wrinkle treatment: Isolagen estimates FDA approval for its autologous cellular "self-therapy" by summer 2005, Vaughan Cliff, VP and medical director, told attendees at the Feb. 9 Aesthetic Technologies Forum in Washington, D.C. Starting with a 3 mm x 7.5 mm patch of biopsied skin from behind the ear, the treatment cultures fibroblasts, which are reinserted into the patient's dermis, regenerating collagen and tissue. Burn and acne applications also are under consideration. The ten-site, double-blind, 152-patient, Phase III wrinkle trial began in August under an investigational new drug application and will include four-month follow-up. Data analysis is due in March, with a marketing submission expected in November or December...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.